Sorafenib (Tosylate) [475207-59-1]
Cat# HY-10201A-500mg
Size : 500mg
Brand : MedChemExpress
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator.
For research use only. We do not sell to patients.
Sorafenib Tosylate Chemical Structure
CAS No. : 475207-59-1
This product is a controlled substance and not for sale in your territory.
Based on 194 publication(s) in Google Scholar
Other Forms of Sorafenib Tosylate:
- Sorafenib In-stock
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]
- Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]
- Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]
- Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]
- SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]
- The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]
- VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]
- The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]
- Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]
- Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]
- Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]
- The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).
-
Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]
- The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).